Answers are grounded in this paper and cite their sources.
The loss of the tumor target antigen, CD20, occurred in 16% of patients with relapse or refractory follicular lymphoma. Due to confounding factors in patients who received anti-CD20 immunotherapy, it was not possible to formally establish the prognostic significance of CD20 negativity. However, we suggest that a check for CD20 antigen positivity nevertheless be performed to adapt subsequent therapies for patients with relapsed or refractory follicular lymphoma.
No takes yet. Share an insight, caveat, or question.
Michot et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: